TY - JOUR
T1 - Activin A causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells
AU - Yoshinaga, Keiji
AU - Yamashita, Keishi
AU - Mimori, Koshi
AU - Tanaka, Fumiaki
AU - Inoue, Hiroshi
AU - Mori, Masaki
N1 - Funding Information:
This work was supported in part by the following grants and foundations: a Grant-in-Aid for Scientific Research on Priority Areas of Cancer (14026037, 15023245) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a Grant-in-Aid for Scientific Research (B) (14370358, 15390398, 15390379, 16390381) and (C) (14570149, 14571140, 15591412, 15591411); and a Grant-in-Aid for Exploratory Research (14657286, 16659337) from the Japan Society for Promotion of Science.
PY - 2008/1
Y1 - 2008/1
N2 - Background: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer. Methods: To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)- transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis. Results: Both Act-βA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration. Conclusions: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.
AB - Background: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer. Methods: To clarify the aggressive behavior of tumors with high activin A expression, we used the β subunit of activin A to establish stable activin βA (Act-βA)- transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis. Results: Both Act-βA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-βA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-βA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration. Conclusions: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.
UR - http://www.scopus.com/inward/record.url?scp=38049152697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38049152697&partnerID=8YFLogxK
U2 - 10.1245/s10434-007-9631-1
DO - 10.1245/s10434-007-9631-1
M3 - Article
C2 - 17909904
AN - SCOPUS:38049152697
SN - 1068-9265
VL - 15
SP - 96
EP - 103
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 1
ER -